Category: clinical study retractions

Rabies paper retracted for plagiarism, and more from the Journal of Clinical Pathology

A cardinal (if oft-broken) rule of headline writing is to avoid the use of question marks. We think it’s particularly important to do so when the potential for ironic misadventure lurks.

To wit: The Journal of Clinical Pathology (JCP) has withdrawn/retracted a 2008 paper by a group of Indian authors (from the National Institute of Mental Health and Neuro Sciences, at Deemed University) whose cliff-hanging title asks the question “Tracking the footprints of the rabies virus: are we any closer to decoding this elusive virus?” Continue reading Rabies paper retracted for plagiarism, and more from the Journal of Clinical Pathology

University of Perugia researcher faces trial for embezzlement, fraud following 13 retractions and Expressions of Concern

Stefano Fiorucci, a gastroenterology researcher at the University of Perugia in Italy, has been indicted for fraud and embezzlement, after a university investigation found that he had manipulated images in papers that he used to win about 2 million Euros in grant funding.

The case, which has so far resulted in four retractions and nine Expressions of Concern, has dragged on for several years. The trial is scheduled for July. It’s the first time that embezzlement charges have been brought against a scientist found to have committed fraud, according to reports in Umbria 24 and the Umbria Journal.

Fiorucci’s attorney, Stefano Bagianti, told Umbria 24 that there was Continue reading University of Perugia researcher faces trial for embezzlement, fraud following 13 retractions and Expressions of Concern

Errors force retraction of Blood paper on genetics of Hodgkin’s lymphoma

The authors of a paper published last September in Blood about alleged links between certain genes and Hodgkin’s lymphoma have retracted it, after realizing they’d made mistakes in their calculations.

The retraction notice for “Multiple HLA class I and II associations in classical Hodgkin lymphoma and EBV status defined subgroups,” dated January 20 and signed by all of the authors, clearly explains what went wrong, taking pains to note that there was no misconduct involved: Continue reading Errors force retraction of Blood paper on genetics of Hodgkin’s lymphoma

So how peripheral was Dipak Das’ resveratrol work, really?

In the wake of the massive allegations of fraud by resveratrol researcher Dipak Das, other researchers in the field are clearly trying to distance themselves from the University of Connecticut scientist. Nir Barzilai told us yesterday, for example, that despite Das seemingly’ impressive publication record, “Rome was not built on Dr. Das.”

Harvard’s David Sinclair went further, telling The New York Times that he didn’t know who Das was: Continue reading So how peripheral was Dipak Das’ resveratrol work, really?

Resveratrol fraud case update: Dipak Das loses editor’s chair, lawyer issues statement refuting all charges

Das, via UConn

Many Retraction Watch readers will now be familiar with the case of Dipak Das, the resveratrol researcher about whom the University of Connecticut issued a voluminous report yesterday — summary here — detailing 145 counts of data fabrication and falsification. This has been a fast-moving story, so we wanted to highlight a number of updates to our original post, and offer a few more.

First, we have confirmed with publisher Mary Ann Liebert this morning that Das has been relieved of his duties as co-editor in chief of Antioxidants & Redox Signaling. He had shared that post with Chandan Sen, and his name as been removed from the masthead of that journal. Here’s a statement from the publisher: Continue reading Resveratrol fraud case update: Dipak Das loses editor’s chair, lawyer issues statement refuting all charges

UConn resveratrol researcher Dipak Das fingered in sweeping misconduct case

Das, via UConn

The University of Connecticut, in what clearly seems like an attempt to get ahead of damaging news, has announced an “extensive” investigation into research misconduct involving one of its scientists, Dipak K. Das.

According to a press release, the university has notified 11 journals that published Das’ work about the alleged fraud. One area of interest for Das, a government-funded professor of surgery and director of the Cardiovascular Research Center, has been resveratrol, a substance in red wine that has allegedly been linked to improved cardiac health.

The university touted some of his early efforts in this field.

[Please also see our update posted Thursday.]

Here’s what the release has to say: Continue reading UConn resveratrol researcher Dipak Das fingered in sweeping misconduct case

Eye of the needle? Paper about camels gets rejected, then published, then retracted

photo by http://www.flickr.com/photos/bysheribeari/ via Flickr

If there’s one thing worse than having your paper rejected by a journal, it’s having it retracted. But usually a paper has to be accepted before it’s published and withdrawn.

Not so for a study from the United Arab Emirates, “Detection and genotyping of GB virus-C in dromedary camels in the United Arab Emirates,” published in 2010 in Veterinary Microbiology.

The editors of the journal ruminated — hey now! is this thing on? — on the paper,  only to give it the thumbs down. But come to find out, it got published anyway. Thus, the following retraction notice, which appeared online last month: Continue reading Eye of the needle? Paper about camels gets rejected, then published, then retracted

Potti and colleagues retract 2008 JAMA paper

Anil Potti‘s retraction count is now eight with the withdrawal of a 2008 study in the Journal of the American Medical Association (JAMA).

Here’s the notice, which appeared online in JAMA sometime yesterday: Continue reading Potti and colleagues retract 2008 JAMA paper

JCO retracts article from major French cancer group over apparent plagiarism

David Khayat

The Journal of Clinical Oncology (JCO) has retracted a November 2011 editorial by a group of French cancer researchers, including David Khayat, the former head of that country’s National Cancer Institute, over what appears to be fairly extensive plagiarism.

Here’s the notice for the article, “Lymphocyte Infiltration in Breast Cancer: A Key Prognostic Factor That Should Not Be Ignored:” Continue reading JCO retracts article from major French cancer group over apparent plagiarism

Cancer issues expression of concern about two Henschke I-ELCAP lung cancer screening papers

The journal Cancer has issued an Expression of Concern about two lung cancer screening papers long dogged by doubt.

Last April, The Cancer Letter and The New York Times jointly published an investigation into the International Early Lung Cancer Action Program (I-ELCAP) run by Claudia Henschke and David Yankelevitz. Other researchers had already criticized the design and conclusions of that trial, but as the investigation noted, an October 2008 review of the study found that the researchers couldn’t find 90 percent of the subjects’ consent forms, an ethical no-no that jeopardizes as many as 135 papers.

Two papers published in Cancer, in 2000 and 2001, are among those studies, according to the notice (links added), which credits the Times and The Cancer Letter and notes that the journal has referred the case to Federal investigators: Continue reading Cancer issues expression of concern about two Henschke I-ELCAP lung cancer screening papers